History of AbbVie
AbbVie is a global biopharmaceutical company that was founded in 2013, following its separation from Abbott Laboratories. The company’s creation was a strategic move to focus on research and development in the field of immunology, oncology, neuroscience, and other therapeutic areas. AbbVie retained a broad portfolio of drugs, including the well-known Humira, which was a leading treatment for autoimmune diseases like rheumatoid arthritis. This focus on specialty medicines and innovative research propelled AbbVie into becoming a significant player in the global healthcare industry.
The company’s early years were marked by expansion and acquisition, including the high-profile purchase of Allergan in 2020, which strengthened AbbVie’s position in the aesthetic, eye care, and neuroscience markets. This acquisition was part of AbbVie’s strategy to diversify its portfolio and reduce its reliance on Humira, as it faced biosimilar competition. AbbVie also focused on advancing its pipeline of treatments, with significant investments in immunology, cancer, and neuroscience. Through this strategic growth, AbbVie has established itself as a major player in the pharmaceutical industry.
Today, AbbVie continues to focus on advancing medical innovation while navigating challenges such as the transition from Humira’s market dominance to new treatments. With a robust pipeline and a diverse range of therapeutic areas, AbbVie remains committed to improving patient outcomes and addressing unmet medical needs worldwide.